• レポートコード:TMRGL73763 • 出版社/出版日:Transparency Market Research / 2022年10月26日 • レポート形態:英文、PDF、241ページ • 納品方法:Eメール • 産業分類:医薬品 |
Single User | ¥869,250 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,319,250 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
※当レポートは英文です。下記の日本語概要・目次は自動翻訳を利用し作成されました。正確な概要・目次はお問い合わせフォームからサンプルを請求してご確認ください。
慢性閉塞性肺疾患(COPD)治療薬の世界市場紹介
慢性閉塞性肺疾患は、肺に影響を与え、呼吸困難を引き起こす疾患群です。慢性気管支炎と肺気腫は、慢性閉塞性肺疾患の2つの主要なタイプです。息苦しさは、COPDの主な特徴です。肺気腫の場合、肺の中の肺胞(小さな空気の袋)が損傷しています。肺胞の壁が引き伸ばされ、肺が大きくなり、空気の移動が困難になります。慢性気管支炎は、肺の中の気管支(呼吸する管)に炎症が起こります。世界的にCOPDの有病率が高く、COPD治療薬のパイプラインが豊富であることが、予測期間中の世界市場の牽引役と考えられます。さらに、老年人口の増加や様々な年齢層における不健康なライフスタイルの選択が、近い将来、慢性閉塞性肺疾患(COPD)治療市場を推進すると予測されます。
世界的なCOPDの有病率の上昇
慢性閉塞性肺疾患(COPD)は、世界中の多くの人々に影響を及ぼす主要な健康上の懸念事項です。疾病負担は増加しており、それによってCOPD管理の必要性が高まっています。タバコの喫煙はCOPDにつながる可能性があります。喫煙習慣のある成人の数は、世界中で増加傾向にあります。その他の危険因子としては、職業や室内空気汚染などがあります。WHOによると、COPDの主な原因はタバコの煙への暴露(能動喫煙、受動喫煙のいずれか)であるとされています。同機関によると、慢性閉塞性肺疾患(COPD)は世界第3位の死因であり、2019年の死亡者数は323万人を占めます。70歳未満のCOPDによる死亡の90%近くは、低・中所得国(LMIC)で発生しています。2022年に発表されたGlobal Initiative for Chronic Obstructive Lung Disease(GOLD)の報告によると、COPDの危険因子にさらされ続けること、間質性肺疾患の発生率の上昇、世界中の高齢化などにより、近い将来、COPDの有病率と負担は増加すると予測されています。これにより、近い将来、慢性閉塞性肺疾患治療薬の市場が拡大すると予想されます。
より効果的な併用療法の採用がCOPD治療薬の世界市場を牽引
併用療法には、LAMA-ICS、LABA-ICS、3剤併用療法、その他の併用薬が含まれます。気管支拡張剤と副腎皮質ホルモンを別々に使用するよりも効果的なため、併用療法の採用が進んでいる。気管支拡張剤や副腎皮質ホルモンの治療では回復の兆しが見られなかった患者が、併用療法によって治療に成功するケースが増加しており、世界の慢性閉塞性肺疾患治療市場の活性化につながると期待されています。併用療法は、単剤療法よりも症状やQOL(生活の質)の改善に有効です。
COPD治療の成功率の向上が、併用療法分野を強化する
COPD治療薬の世界市場は、薬剤の種類によって、併用療法、気管支拡張剤、コルチコステロイド、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、その他に分類されます。2021年の世界市場では、併用療法分野が約50%の主要シェアを占めています。COPD治療における併用療法の有効性が高まっていることから、予測期間中、世界市場を支配する可能性が高いと考えられます。COPD治療における併用療法の成功率の上昇と最近の規制当局による承認は、併用療法の採用を増大させています。これにより、予測期間中、同領域が牽引されると予測されます。
喫煙者の気流障害と呼吸困難の急増が慢性気管支炎セグメントを活性化
COPD治療薬の世界市場は、タイプ別に慢性気管支炎と肺気腫に二分されます。2021年の慢性閉塞性肺疾患治療市場シェアは、慢性気管支炎セグメントが最大となりました。慢性気管支炎は、気流の閉塞と呼吸障害を引き起こす肺疾患群で、喫煙者の間で広く普及しており、急速なペースで増加しています。
COPD治療薬の調剤数の増加が小売薬局のセグメントを押し上げる
世界市場は、販売チャネル別に病院薬局、小売薬局、オンライン薬局に分類されます。小売薬局分野は、予測期間中に慢性閉塞性肺疾患治療薬の世界市場で大きなシェアを占めると予想されます。小売薬局でのCOPD治療薬調剤数の増加や、発展途上国における小売薬局の増加により、予測期間中に急成長が見込まれています。
慢性閉塞性肺疾患(COPD)治療薬市場の地域別概況
慢性閉塞性肺疾患治療薬市場の分析によると、2021年の世界市場のうち、北米が約40%の最大シェアを占めています。同地域の市場は、2022年から2031年にかけてCAGR4.3%で成長すると予測されています。これは、高度に構造化された医療業界と、民間および公的医療保険会社による明確な償還政策が利用可能であることに起因していると思われます。さらに、高度で効率的な製品を提供するための研究開発活動の増加、および多数のプレイヤーの存在が、北米の慢性閉塞性肺疾患治療市場規模を押し上げています。
欧州は、2021年の世界市場で2番目に大きなシェアを占めています。整備された医療インフラと慢性閉塞性肺疾患の罹患率の増加が、同地域のCOPD治療市場を促進しています。
アジア太平洋地域の市場は、予測期間中に最も速いCAGR 4.7%で成長すると予測されます。同地域は、先進地域と比較して慢性閉塞性肺疾患治療市場が比較的未開拓であることが特徴です。そのため、アジア太平洋地域は市場関係者に大きな機会を提供しています。慢性閉塞性肺疾患の高い有病率、老人人口の増加、患者数の急増、医療産業の成長が、同地域の慢性閉塞性肺疾患治療市場を促進しています。
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlight
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Reimbursement Scenario by Region/globally
5.3. Pipeline Analysis
5.4. Technological Advancements
5.5. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
5.6. Disease Prevalence & Incidence Rate globally with key countries
5.7. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.8. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Combination Therapy
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple therapy
6.3.1.4. Others
6.3.2. Bronchodilators
6.3.2.1. Long Acting Beta Agonist (LABA)
6.3.2.2. Short Acting Beta Agonist (SABA)
6.3.2.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.3. Corticosteroids
6.3.4. Phosphodiesterase Type 4 Inhibitor
6.3.5. Mucokinetics
6.3.6. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Chronic Bronchitis
7.3.2. Emphysema
7.4. Market Attractiveness Analysis, by Type
8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Combination Therapy
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple therapy
10.2.1.4. Others
10.2.2. Bronchodilators
10.2.2.1. Long Acting Beta Agonist (LABA)
10.2.2.2. Short Acting Beta Agonist (SABA)
10.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.3. Corticosteroids
10.2.4. Phosphodiesterase Type 4 Inhibitor
10.2.5. Mucokinetics
10.2.6. Others
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. Chronic Bronchitis
10.3.2. Emphysema
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Combination Therapy
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple therapy
11.2.1.4. Others
11.2.2. Bronchodilators
11.2.2.1. Long Acting Beta Agonist (LABA)
11.2.2.2. Short Acting Beta Agonist (SABA)
11.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.3. Corticosteroids
11.2.4. Phosphodiesterase Type 4 Inhibitor
11.2.5. Mucokinetics
11.2.6. Others
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Chronic Bronchitis
11.3.2. Emphysema
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Combination Therapy
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple therapy
12.2.1.4. Others
12.2.2. Bronchodilators
12.2.2.1. Long Acting Beta Agonist (LABA)
12.2.2.2. Short Acting Beta Agonist (SABA)
12.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.3. Corticosteroids
12.2.4. Phosphodiesterase Type 4 Inhibitor
12.2.5. Mucokinetics
12.2.6. Others
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Chronic Bronchitis
12.3.2. Emphysema
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Combination Therapy
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple therapy
13.2.1.4. Others
13.2.2. Bronchodilators
13.2.2.1. Long Acting Beta Agonist (LABA)
13.2.2.2. Short Acting Beta Agonist (SABA)
13.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.3. Corticosteroids
13.2.4. Phosphodiesterase Type 4 Inhibitor
13.2.5. Mucokinetics
13.2.6. Others
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Chronic Bronchitis
13.3.2. Emphysema
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Combination Therapy
14.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
14.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
14.2.1.3. Triple therapy
14.2.1.4. Others
14.2.2. Bronchodilators
14.2.2.1. Long Acting Beta Agonist (LABA)
14.2.2.2. Short Acting Beta Agonist (SABA)
14.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
14.2.3. Corticosteroids
14.2.4. Phosphodiesterase Type 4 Inhibitor
14.2.5. Mucokinetics
14.2.6. Others
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. Chronic Bronchitis
14.3.2. Emphysema
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Mylan N.V.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Boehringer Ingelheim International GmbH
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. CHIESI Farmaceutici S.p.A.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Orion Corporation
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Almirall
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Theravance Biopharma
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Verona Pharmaceuticals
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Kyowa Hakko Kirin
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Product Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview
List of Tables
Table 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Combination Therapy
Table 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Bronchodilators
Table 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 09: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031
Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031
Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031
Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031
Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 19: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031
Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031
Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031
Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031
Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 30: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031
Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031
Table 35: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 36: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031